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Introduction
Paclitaxel is widely used to treat patients with cancers of the lung, breast, stomach, endometrium or ovary [Kohler DR and Goldspiel BR, 1994] . However, it causes a wide range of side effects such as vomiting, hematopoietic disorders and painful peripheral neuropathy [Rowinsky EK et al., 1993; Kohler DR and Goldspiel BR, 1994; Cata JP et al., 2006; Hausheer FH et al., 2006] . Paclitaxel-induced peripheral neuropathy becomes more marked with continued therapy, and it is often the dose-limiting toxicity. Although massage therapy, amino acids, vitamin supplements and analgesics have been used to treat this neuropathy, their efficacy is low and there is no preventive therapy [Vahdat L et al., 2001; Hausheer FH et al., 2006; Kaley TJ and DeAngelis LM, 2009 ].
Paclitaxel-treated mice or rats have been used as animal models of paclitaxel-induced peripheral neuropathy. These models reproduce many of the symptoms of paclitaxel-induced peripheral neuropathy in humans, including mechanical allodynia, thermal hyperalgesia, and thermal hypoalgesia [Polomano RC et al., 2001; Cata JP et al., 2006; Xiao W et al., 2008] . Various drugs have been investigated in these models, and gabapentin (a calcium channel α J P E T # 1 8 7 4 0 1
Although prostanoids produced by cyclooxygenase 2 (COX-2) mediate the inflammatory cascade and have been suggested to contribute to the development of peripheral neuropathy in animal models [Ma W and Eisenach JC, 2002, 2003; Durrenberger PF et al., 2004; Schäfers M et al., 2004] , COX inhibitors are not considered effective in the clinical management of neuropathy. However, we have
shown that the COX-2 inhibitor etodolac strongly ameliorates the mechanical allodynia induced by partial sciatic nerve ligation in mice, whereas other COX inhibitors do not [Inoue N et al., 2009] . It is therefore possible that etodolac would also ameliorate paclitaxel-induced neuropathy.
In the present study, we investigated the effect of etodolac on mechanical allodynia in a mouse model and compared it with that of other COX inhibitors and analgesic agents used to treat peripheral neuropathic pain. Etodolac, but not other COX inhibitors, ameliorated the mechanical allodynia induced by paclitaxel.
JPET Fast Forward. Published on March 29, 2012 as DOI: 10.1124 at ASPET Journals on July 9, 2017 jpet.aspetjournals.org ventilation frequency of at least 15 times/h. They were allowed free access to pellet chow (F-2; Funabashi Farm, Funabashi, Japan) and tap water.
Reagents
Paclitaxel was purchased from Xi'an Tiancheng Drugs & Bio-engineering (Xian, Shaanxi, China), diclofenac from Daiwa Pharmaceutical (Toyama, Japan), and indomethacin and mexiletine from Sigma-Aldrich (St. Louis, MO, USA). Etodolac, pregabalin and duloxetine were synthesized and celecoxib was extracted from Celebrex capsules (Pfizer, New York, NY, USA) in our laboratories. Etodolac, indomethacin, celecoxib, diclofenac, pregabalin, duloxetine, and mexiletine were suspended in 0.5%
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J P E T # 1 8 7 4 0 1 9 methylcellulose solution and administered orally through a stainless-steel gavage tube.
Mouse model of paclitaxel-induced allodynia
Paclitaxel was dissolved in ethanol:cremophor:saline (5:5:90, v/v/v) to a concentration of 0.4 mg/ml and injected intraperitoneally at a dose of 4 mg/kg on four nonconsecutive days (days 0, 2, 5, and 7) as previously described [Matusmoto M et al., 2006] . Mice injected with ethanol:cremophor:saline vehicle only were used as normal mice. For therapeutic treatment, drugs were administered orally once a day for two weeks from day 8, and mice injected with 0.5% methylcellulose vehicle only were used as control mice. The paw-withdrawal threshold (PWT) was measured with von Frey filaments (North Coast Medical, Morgan Hill, CA, USA) as described below once a week (days 8, 15, and 22) before drug administration and either 0.5 and 4 h or 1 and 4 h after administration.
Assessment of mechanical allodynia (von Frey filament test)
Mechanical allodynia was assessed as previously described [Inoue N et al., 2009] .
Briefly, each mouse was acclimated alone in a perspex box on a raised metal mesh for at Conversely, if no response was observed, a filament one size larger was tried. In this way, the minimum filament size (in grams) required to produce a positive response in at least three of 10 trials was determined and taken as the value of PWT.
Cell proliferation assay
The human non-small-cell lung cancer cell line A549 was purchased from Health 
Histopathological analysis
Mice were injected with paclitaxel (20 mg/kg) intravenously on five nonconsecutive days (days 1, 3, 6, 8, and 10). Etodolac (10 mg/kg) was administered to paclitaxel-treated animals orally once a day for 17 days from day 0. 
Statistical analysis
In the paclitaxel-induced allodynia model, statistically significant differences in PWT between normal groups (mice not treated with paclitaxel) and control groups Fig. 2A) . Until day 15, the preadministration PWT was not significantly different from the control value, but it had significantly increased by day 22. Duloxetine at 30 and 100 mg/kg p.o. increased the PWT of paclitaxel-treated mice ( Fig. 2B ), but these doses tended to cause sedation.
Mexiletine at 30 and 100 mg/kg p.o. similarly increased the PWT of paclitaxel-treated mice ( Fig. 2C ), but these doses also caused sedation.
Effect of etodolac, pregabalin, duloxetine and mexiletine on the PWT of normal mice
The effect on the PWT of normal mice of etodolac, pregabalin, duloxetine and mexiletine, which had antiallodynic effects in paclitaxel-treated mice, was examined ( Fig. 3 ). Etodolac (10 mg/kg) did not affect the PWT of normal mice after a single or repeated administration. Duloxetine and mexiletine also had no effect on the PWT of normal mice after administration on day 0, but they slightly decreased the PWT at 1 and
mice at 1 and 4 h after administration on days 0 and 8, and the effect at 4 h on day 0 was significant.
Effect of etodolac on antiproliferative activity of paclitaxel
It is important that etodolac attenuates only the adverse effect of paclitaxel without weakening its antitumor activity. We therefore examined the antiproliferative effect of paclitaxel on human cancer cell lines in the presence of increasing concentrations of etodolac. Etodolac itself did not have an antiproliferative effect on the human lung adenocarcinoma epithelial cell line A549, and it also did not affect the antiproliferative activity of paclitaxel against that cell line (Fig. 4A) . At 100 μ M, the highest dose tested, etodolac slightly inhibited the proliferation of the human breast adenocarcinoma cell line MDA-MB468 (Fig. 4B ) and the human ovarian carcinoma cell line OVCAR (Fig. 4C ). In addition, etodolac tended to increase the antiproliferative activity of paclitaxel against MDA-MB468 cells (Fig. 4B ). (Fig. 5) .
Histopathology of peripheral nervous tissue in normal and paclitaxel-treated mice
To assess whether the mechanism of action of etodolac might involve a neuroprotective effect, we performed histopathological examination of dorsal root, dorsal cord and sciatic nerves in normal and paclitaxel-treated mice. In a preliminary
This article has not been copyedited and formatted. The final version may differ from this version. Table 2 ). Paclitaxel treatment also led to significantly increased numbers of degenerating nerve fibers, and etodolac treatment again had no noticeable histopathological improvement ( Fig. 6G-I ; Table 3 ).
This article has not been copyedited and formatted. The final version may differ from this version. 20 attributed to residual drug. The effects of the analgesic agents pregabalin, mexiletine and duloxetine, which are used to treat peripheral neuropathic pain, were tested in the same model. The effect of pregabalin was similar to that of etodolac in that it gradually increased its effect on repeated administration and showed an effect at the preadministration point after two weeks' administration. Mexiletine and duloxetine showed no such effect. However, pregabalin increased the paw-withdrawal threshold in normal mice, whereas etodolac did not. This result suggests that etodolac has therapeutic efficacy against paclitaxel-induced peripheral neuropathy without suppressing normal nerve activity.
The mechanism by which etodolac suppresses paclitaxel-induced peripheral neuropathy is unknown. Before investigating the mechanism, we first tested whether etodolac affected the antitumor activity of paclitaxel. [Yanaoka K et al., 2010] . Therefore, administration of etodolac with paclitaxel may not only be useful for reducing the adverse neurological effects of paclitaxel but may even enhance its antitumor activity.
As the second part of our study on the mechanism by which etodolac suppresses paclitaxel-induced peripheral neuropathy, we investigated the distribution of etodolac in that is different from that of diclofenac. The fact that there was no appreciable difference in the nerve-tissue distribution of the two compounds suggests that the effect of etodolac is mediated by a mechanism other than COX inhibition.
As the third and final part of our study, we carried out a histopathological examination of peripheral nervous tissues in normal and paclitaxel-treated mice. The pathogenesis of paclitaxel-induced peripheral neuropathy has not been fully elucidated, but it has been suggested that paclitaxel promotes the aggregation of intracellular microtubules and stabilizes them [Hausheer FH et al., 2006] . This would inhibit axonal 
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